Literature DB >> 29617983

Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?

Monica Fung1, Brian S Schwartz1, Sarah B Doernberg1, Charles Langelier1, Mimi Lo2, Larissa Graff2, Marisela Tan2, Aaron C Logan3, Peter Chin-Hong1, Jennifer M Babik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29617983      PMCID： PMC6692592          DOI： 10.1093/cid/ciy260

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  Antifungal prophylaxis in lung transplantation--a world-wide survey.

Authors:  C F Neoh; G I Snell; T Kotsimbos; B Levvey; C O Morrissey; M A Slavin; K Stewart; D C M Kong
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

Review 2.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors:  Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

3.  Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.

Authors:  Frederic Lamoth; Shimin J Chung; Lauro Damonti; Barbara D Alexander
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

4.  Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.

Authors:  Oliver A Cornely; Angelika Böhme; Anne Schmitt-Hoffmann; Andrew J Ullmann
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

5.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Authors:  Johan A Maertens; Issam I Raad; Kieren A Marr; Thomas F Patterson; Dimitrios P Kontoyiannis; Oliver A Cornely; Eric J Bow; Galia Rahav; Dionysios Neofytos; Mickael Aoun; John W Baddley; Michael Giladi; Werner J Heinz; Raoul Herbrecht; William Hope; Meinolf Karthaus; Dong-Gun Lee; Olivier Lortholary; Vicki A Morrison; Ilana Oren; Dominik Selleslag; Shmuel Shoham; George R Thompson; Misun Lee; Rochelle M Maher; Anne-Hortense Schmitt-Hoffmann; Bernhardt Zeiher; Andrew J Ullmann
Journal:  Lancet       Date:  2015-12-10       Impact factor: 79.321

6.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Authors:  Francisco M Marty; Luis Ostrosky-Zeichner; Oliver A Cornely; Kathleen M Mullane; John R Perfect; George R Thompson; George J Alangaden; Janice M Brown; David N Fredricks; Werner J Heinz; Raoul Herbrecht; Nikolai Klimko; Galina Klyasova; Johan A Maertens; Sameer R Melinkeri; Ilana Oren; Peter G Pappas; Zdeněk Ráčil; Galia Rahav; Rodrigo Santos; Stefan Schwartz; J Janne Vehreschild; Jo-Anne H Young; Ploenchan Chetchotisakd; Sutep Jaruratanasirikul; Souha S Kanj; Marc Engelhardt; Achim Kaufhold; Masanori Ito; Misun Lee; Carolyn Sasse; Rochelle M Maher; Bernhardt Zeiher; Maria J G T Vehreschild
Journal:  Lancet Infect Dis       Date:  2016-03-09       Impact factor: 25.071

7.  Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.

Authors:  K M T Astvad; R K Hare; M C Arendrup
Journal:  Clin Microbiol Infect       Date:  2017-04-01       Impact factor: 8.067

Review 8.  Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Authors:  Sibylle C Mellinghoff; Jens Panse; Nael Alakel; Gerhard Behre; Dieter Buchheidt; Maximilian Christopeit; Justin Hasenkamp; Michael Kiehl; Michael Koldehoff; Stefan W Krause; Nicola Lehners; Marie von Lilienfeld-Toal; Annika Y Löhnert; Georg Maschmeyer; Daniel Teschner; Andrew J Ullmann; Olaf Penack; Markus Ruhnke; Karin Mayer; Helmut Ostermann; Hans-H Wolf; Oliver A Cornely
Journal:  Ann Hematol       Date:  2017-12-07       Impact factor: 3.673
  8 in total
  17 in total

1.  Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.

Authors:  Xuemei Wu; Raman Venkataramanan; Ryan M Rivosecchi; Chenxiao Tang; Rachel V Marini; Ryan K Shields; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.

Authors:  Erin K McCreary; M Hong Nguyen; Matthew R Davis; Jared Borlagdan; Ryan K Shields; Anthony D Anderson; Ryan M Rivosecchi; Rachel V Marini; Lauren M Sacha; Fernanda P Silveira; David R Andes; Alexander J Lepak
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

Review 3.  Diagnosis and Treatment of Acute Invasive Fungal Sinusitis in Cancer and Transplant Patients.

Authors:  Monica Fung; Jennifer Babik; Ian M Humphreys; Greg E Davis
Journal:  Curr Infect Dis Rep       Date:  2019-11-26       Impact factor: 3.725

4.  Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.

Authors:  Kathleen A Linder; Tejal N Gandhi; Marisa H Miceli
Journal:  Mycopathologia       Date:  2019-08-26       Impact factor: 2.574

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

Authors:  Matthew W McCarthy; Brad Moriyama; Ruta Petraitiene; Thomas J Walsh; Vidmantas Petraitis
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

6.  Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.

Authors:  Caitlin R Rausch; Adam J DiPippo; Prithviraj Bose; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

7.  A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Authors:  Anat Stern; Yiqi Su; Yeon Joo Lee; Susan Seo; Brian Shaffer; Roni Tamari; Boglarka Gyurkocza; Juliet Barker; Yael Bogler; Sergio Giralt; Miguel-Angel Perales; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-20       Impact factor: 5.742

8.  Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions.

Authors:  Michail S Lionakis; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

9.  Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Authors:  M Biagi; D Butler; X Tan; S Qasmieh; K Tejani; S Patel; R M Rivosecchi; M H Nguyen; C J Clancy; R K Shields; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

10.  Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole.

Authors:  Malene Risum; Mai-Britt Vestergaard; Ulla Møller Weinreich; Marie Helleberg; Nadja Hawwa Vissing; René Jørgensen
Journal:  Antibiotics (Basel)       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.